PRESS RELEASE published on 10/02/2023 at 18:00, 2 years 5 months ago Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
PRESS RELEASE published on 10/02/2023 at 18:00, 2 years 5 months ago Abivax met en avant son programme de développement clinique d’obefazimod dans la rectocolite hémorragique avec de nouvelles données présentées lors de la conférence UEG Week 2023
PRESS RELEASE published on 09/29/2023 at 23:00, 2 years 5 months ago Abivax files registration statement for proposed initial public offering in the United States
PRESS RELEASE published on 09/29/2023 at 23:00, 2 years 5 months ago Abivax annonce le dépôt d’un document d’enregistrement form F-1 en vue de son introduction en bourse envisagée aux Etats-Unis et le dépôt d’un amendement à son document d’enregistrement universel
PRESS RELEASE published on 09/29/2023 at 18:00, 2 years 5 months ago Abivax announces the release of its 2023 half-year financial report
PRESS RELEASE published on 09/29/2023 at 18:00, 2 years 5 months ago Abivax annonce la publication de son rapport financier semestriel 2023
PRESS RELEASE published on 09/27/2023 at 18:00, 2 years 5 months ago ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 31.08.23.
PRESS RELEASE published on 09/21/2023 at 18:00, 2 years 6 months ago Abivax presents first-half 2023 financial results
PRESS RELEASE published on 09/21/2023 at 18:00, 2 years 6 months ago Abivax présente ses résultats financiers semestriels 2023
PRESS RELEASE published on 09/07/2023 at 08:00, 2 years 6 months ago Abivax provides business and operational update
Published on 03/23/2026 at 11:30, 27 minutes ago Trans Canada Gold Provides Update on Non-Brokered Private Placement and Flow-through Private Placement for Drilling at the Harrison Lake District Scale Gold Property Acquisition
Published on 03/23/2026 at 08:00, 3 hours 57 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 57 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 11:44, 12 minutes ago Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 27 minutes ago EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 50 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 51 minutes ago ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 52 minutes ago BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Published on 03/23/2026 at 08:10, 3 hours 47 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
